This page lists feature articles on COVID-19 relevant to people working at St Vincent's Health Australia.
All articles listed are open access unless stated otherwise.
Therapy
Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.
Journal of the American Geriatrics Society:2021: July 8 Full text
Bamlanivimab plus etesevimab in mild or moderate Covid-19.
New England Journal of Medicine:2021: July 14 Full text
Clinical Practice
Remote home monitoring (virtual wards) for confirmed or suspected COVID-19 patients: a rapid systematic review.
EClinicalMedicine:2021: June 22 Full text
Exercise rehabilitation associates with lower mortality and hospitalisation in cardiovascular disease patients with COVID-19.
European Journal of Preventive Cardiology:2021: July 5 Full text
The impact of the COVID-19 pandemic on colorectal cancer diagnosis and management; a binational colorectal cancer audit study. AUS
ANZ Journal of Surgery:2021: July 7 Full text
Pathophysiology
Atherogenic dyslipidemia on admission is associated with poorer outcome in people with and without diabetes hospitalized for COVID-19.
Diabetes Care:2021: July 12 Full text
Long COVID in a prospective cohort of home-isolated patients.
Nature Medicine:2021: June 23 Full text
Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study.
Clinical Infectious Diseases: 2021: July 5 Full text
Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study.
Lancet Child and Adolescent Health:2021: July 14 Full text
Vaccines
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
Lancet:2021: July 8 Full text
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
New England Journal of Medicine:2021: July 14 Full text
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
Nature Medicine:2021: July 14 Full text
Durable humoral and cellular immune responses 8 months after Ad26.COV2.S Vaccination.
New England Journal of Medicine:2021: July 14 Full text
Immunology
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. SVHA
PLOS Medicine:2021: July 6 Full text
Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance.
Nature Communications:2021: July 13 Full text
